lobbying_activities: 1555746

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
1555746	4a2a221a-abbf-4ae1-a0ca-0c8933b48c72	Q2	AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS	3457	AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS	2014	second_quarter	PHA	Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, and implementation of the Drug Quality and Security Act. Contact concerning HRSA oversight of 340B drug discount program. Communication with the OIG on Compendia . Contact concerning the Drug Quality and Security Act, H.R. 3204, all titles. Communication with the FDA on labeling of generic medications and drugs containing salts. Communication with FTC on biosimilars. Support for H.R. 3742, all titles, theAntibiotic Development to Advance Patient Treatment Act.	Centers For Medicare and Medicaid Services (CMS),Federal Trade Commission (FTC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE		250000	0	0	2014-07-17T12:53:33.483000-04:00